Roche to withdraw US accelerated approval for Tecentriq to treat breast cancer

Roche to withdraw US accelerated approval for Tecentriq to treat breast cancer

Source: 
Pharmaceutical Business Review
snippet: 

Roche has decided to voluntarily withdraw the US accelerated approval for Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) to treat patients with PD-L1-positive metastatic triple-negative breast cancer (mTNBC).